Synergen Met's CEO and managing director, Christopher Dunks, was featured in Stockhead discussing the company and its IPO.

Synergen Met has recently been named one of Stockhead’s IPOs to watch with the company looking to list in June with a IPO valuation of $120-125m at a $20-25m placement.

Chris Dunks and his team, mainly from the University of Queensland, have been working with  plasma technology with the aim to efficiently minimise waste and destroy per-fluorinated alkylated substances (PFAS).

Chris discusses fighting the future with hydrogen:

“...Over the last 14 years, through a combination of research, innovation, a lot of trial and error in the lab, and through extensive field trials, Synergen has been able to leverage and deploy our Thermal Plasma Technology platform into multiple high-value applications.”

Christopher Dunks, Managing Director, Synergen Met Limited.

What is PFAS?

Per-fluorinated alkylated substances (PFAS) are persistent, bioaccumulative and toxic (PBT). They are found all over the world and our waterways.

Chris states:

“Even now, when we talk about the ‘forever’ chemical, PFAS, heaps of us still see red.

Synergen is rolling out innovative, proprietary technology that concentrates the PFAS molecule and then destroys it, converting it to a harmless, non-toxic substance.”

Perfect timing 

Since Glascow COP26, the community worldwide has started to seek change in the way large corporations approach their duty to address the climate crisis. Since then, a giant breakthrough is the emergence of clean hydrogen, which is good news for Synergen Met. 

“A major part of the revolution that is needed in reducing and eliminating greenhouse gas emissions involves hydrogen... Synergen is building capability to play a leading role in both the production of clean hydrogen and the rolling out of the enabling technology.”

Christopher Dunks, Managing Director, Synergen Met Limited.

Synergen Met is already operating with fully developed patented technology and innovative applications that the industry is clamouring for right now. Aside from Synergen’s existing applications, they have also acquired Phoenix Solutions Co (Phoenix), a business with over 50 years experience, specialising in the production of high temperature plasma equipment.

Post-IPO

Dunks claims that after the IPO, SH2 will begin its hydrogen roll-out strategy with the TLOU Energy project, including the construction of two PFAS destruction facilities, multiple PFAS concentration facilities, fabrication and operation of a carbon separation facility, and working capital injection into Phoenix.

Chris says:

"Everything we do is about efficiency and minimising waste. That’s why we only ever advance the company’s strategy and business goals in an absolutely cost-effective manner,”

"When we go public that’ll remain part of our mantra – a beautiful solution, delivered cleanly, efficiently, for everyone.”

Read the full Stockhead article here.

Synergen Met 

Synergen Met is an Australian-owned and operated business made up of a team of scientific minds with more than 80 years of collective experience working within the global resources industry. Founders, Christopher Dunks and Dr Geoff Duckworth, have developed the Company’s Thermal Plasma Technology over the last 14 years.

Attention Investors

Synergen Met Ltd (ASX:SH2) is seeking to raise A$25m at an issue price of $0.20 per share, together with two (2) free attaching Options for every four (4) Shares subscribed for and issued (Public Offer). Synergen Met's IPO is now live, click below to register your interest.

If you would like to learn more about Synergen Met, or if you would like to keep up to date with their news and progress, subscribe to the Synergen Met Limited Chairman's List.